Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metastatic prostate cancer: EBRT improves survival in elderly patients with low PSA

Key clinical point: External beam radiation therapy (EBRT) was associated with reduced mortality in metastatic prostate cancer patients with low prostate-specific antigen (PSA) and intermediate life expectancy (5-10 years).

Major finding: The median overall survival was 45 vs. 35 months in EBRT vs. no EBRT patients (P less than .001). EBRT was an independent predictor of lower overall mortality (hazard ratio [HR], 0.7; P = .001). EBRT was associated with lower overall mortality in M1a (HR, 0.2; P = .03) and M1b (HR, 0.7; P = .003) substages.

Study details: This study included 835 newly diagnosed M1a or M1b metastatic prostate cancer patients with PSA less than 20 ng/mL and with intermediate life expectancy, treated with EBRT (n = 179) or no EBRT (n = 656) from the Surveillance, Epidemiology, and End Results database (2004-2016).

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation:

Stolzenbach LF et al. Urol Oncol. 2020 Nov 11. doi: 10.1016/j.urolonc.2020.10.011.